



NCPE Plain English Summary

Drug name: Midostaurin (*pronounced: MY-doh-STAW-rin*) (*with daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy*) followed by midostaurin monotherapy for up to 12 months, for the treatment of newly diagnosed adult patients with FLT3 mutation-positive acute myeloid leukaemia (AML).

Brand name: Rydapt®

What is the NCPE?

The National Centre for Pharmacoeconomics (NCPE) is a team of experts who look at the health benefits and costs of medicines. The HSE asks us to advise on whether or not a new medicine is good value for money. We give unbiased advice to help the HSE provide the most effective, safe and cost-effective (value for money) treatments for patients.

How do we make our recommendations?

Our main focus is on the health benefits and cost effectiveness of a medicine. We look at the wider costs and health benefits associated with a new medicine, for example:

- Does the new medicine work better than other treatments available in Ireland?
- Is the new medicine easier to give or easier to take compared with other treatments available in Ireland?
- Does the new medicine reduce the need for patients to be hospitalised?
- Does the new medicine improve the quality of a patient's life over other treatments available in Ireland?
- Will the new medicine save resources elsewhere within the health system?

We review the information from clinical trials along with the cost and value for money data presented by the pharmaceutical company. We ask doctors and other healthcare professionals for advice about any health benefits of the new medicine compared with current treatments. We also ask patient organisations to send us their views on how the new drug may improve patients' day-to-day experience of living with a disease.

What is midostaurin used for?

Midostaurin is a cancer medicine used in combination with chemotherapy medicines initially, and then on its own if the disease has responded to treatment. It is used to treat adults with

newly diagnosed acute myeloid leukaemia (AML), a cancer of the white blood cells. It is only used when the AML has a particular genetic change called an FLT3 mutation.

What recommendation has the NCPE made to the HSE?

We have recommended that the HSE should consider not funding midostaurin unless its cost effectiveness (value for money) can be improved. The HSE will consider our recommendation and make the final decision about reimbursement (funding). When making the funding decision, the HSE will also consider the additional [criteria](#) outlined in the Health (Pricing and Supply of Medical Goods) Act 2013.

Why did we make this recommendation?

We have completed a full health technology assessment for this medicine. We recommend that the HSE consider **not** providing this medicine unless the HSE can agree a suitable price reduction with the pharmaceutical company. This is because we believe the medicine works as well or better than other ways to manage this condition. However, the price of the medicine is too high compared with other ways to manage this condition, and we believe that the medicine is very poor value for money.

Next steps

When the HSE receives our recommendation, it will look at all the relevant data about midostaurin. The HSE makes the final decision on reimbursement.

Where can I get more information?

You can get more information about midostaurin from the following online options:

- the NCPE Technical Summary Document
- Midostaurin European Public Assessment Report (EPAR) – [Summary for the public](#)
- searching for the medicine name on our website (www.ncpe.ie):
- searching for the medicine name on the European Medicines Agency (EMA) website (www.ema.europa.eu).

Please refer to the NCPE website for updated information on the reimbursement status of this medicine.

Date published: December 2019